This Article Full Text Full Text (PDF) All Versions of this Article: JOE-09-0431v1 205/3/201    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Permissions information Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perrini, S. Articles by Giorgino, F. Search for Related Content PubMed PubMed Citation Articles by Perrini, S. Articles by Giorgino, F. Social Bookmarking                               What's this?

Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari School of Medicine, Piazza Giulio Cesare, 11, I-70124 Bari, Italy

(Correspondence should be addressed to F Giorgino; Email: f.giorgino{at}endo.uniba.it)

The widespread increase in life expectancy is accompanied by an increased prevalence of features of physical frailty. Signs and symptoms may include sarcopenia and osteopenia, reduced exercise capacity, and diminished sense of well-being. The pathogenesis of age-associated sarcopenia and osteopenia is multifactorial, and hormonal decline may be a contributing factor. Aging is associated with a progressive decrease in GH secretion, and more than 30% of elderly people have circulating IGF1 levels below the normal range found in the young. GH acts directly on target tissues, including skeletal muscle and bone among many others, but many effects are mediated indirectly by circulating (liver-derived) or locally produced IGF1. Aging is also associated with reduced insulin sensitivity which, in turn, may contribute to the impairment of IGF1 action. Recent experimental evidence suggests that besides the age-dependent decline in GH and IGF1 serum levels, the dysregulation of GH and IGF1 actions due to impairment of the post-receptor signaling machinery may contribute to the loss of muscle mass and osteopenia. This article will focus on the molecular mechanisms of impaired GH and IGF1 signaling and action in aging, and their role in the pathogenesis of sarcopenia and osteoporosis.

CiteULike    Complore    Connotea    Delicious    Digg    Facebook    LinkedIn    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. J. Marie and M. Kassem Extrinsic Mechanisms Involved in Age-Related Defective Bone Formation J. Clin. Endocrinol. Metab., March 1, 2011; 96(3): 600 - 609. [Abstract] [Full Text] [PDF]

				D. G. Taekema, C. H. Y. Ling, G. J. Blauw, C. G. Meskers, R. G. J. Westendorp, A. J. M. de Craen, and A. B. Maier Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women Eur. J. Endocrinol., February 1, 2011; 164(2): 189 - 196. [Abstract] [Full Text] [PDF]